Muna Therapeutics, a biotech company co-located in Denmark and Belgium, has received a $4.9 million grant from the Michael J Fox Foundation of the US to support preclinical research and development into small molecule potassium channel type 1.3 (Kv1.3) blockers to stop neuroinflammation and enhance neuroprotection in Parkinson’s disease.
